Mach7 Lands $1.7M US Radiology Deal With 45-Day Deployment vs Typical 12 Months

By Josua Ferreira -

Mach7 secures AMRADNET contract with 45-day deployment, a fraction of its typical timeline

Mach7 Technologies (ASX: M7T) has signed a new 5-year annual subscription contract with US teleradiology provider American Radiologist Network Inc. (AMRADNET) for its eUnity Viewer. The agreement carries an initial contract value of A$1.7M, based on a minimum of 0.675M studies per annum, with volumes projected to exceed 1M studies over the 5-year term. Effective 20 May 2026, the deal is notable not only for its commercial value but for an expected First Productive Use (FPU) within just 45 days, a material compression on Mach7’s typical 12-month deployment timeline.

AMRADNET and the US teleradiology opportunity

Founded in 2004, AMRADNET operates a SaaS-based Radiology Informatics Portal that connects US board-certified radiologists with healthcare facilities for remote imaging interpretation and reporting. Its client base spans long-term acute care, skilled nursing institutions, hospitals, outpatient centres, urgent care centres, and diagnostic clinics.

The company is actively extending its reach into cardiology, neurology, and broader telemedicine services. That expansion trajectory is a key factor underpinning the volume projections embedded in the contract.

Why eUnity fits a high-volume teleradiology environment

eUnity is Mach7’s Enterprise Diagnostic Viewer, built for fast, high-volume imaging workflows. AMRADNET’s model, connecting radiologists remotely to a diverse range of facilities via a SaaS platform, demands a viewer that is scalable, interoperable, and cloud-compatible.

These are qualities the announcement attributes directly to eUnity, making the platform a functional fit for AMRADNET’s operating environment rather than a generic capability claim. As AMRADNET grows its clinical reach, the viewer’s capacity to support high imaging volumes becomes increasingly material to the partnership’s value.

What’s behind the 45-day deployment, and why it matters

The 45-day FPU timeline is the standout metric in this announcement. Mach7’s typical deployment runs to approximately 12 months, making the compressed schedule a significant departure from historical norms.

The announcement attributes this improvement directly to the removal of internal silos and the restructuring of Mach7’s sales and services teams. This is not framed as circumstance or client readiness alone; it is presented as evidence of a broader commercial transformation underway at the company.

From evaluation to first productive use — what this signals

The shortened deployment window carries several implications for Mach7’s business model:

  1. Faster time to revenue recognition on new contracts
  2. Lower deployment cost per customer as internal processes become more efficient
  3. Greater scalability for future customer onboarding without proportionally increasing resource requirements
  4. A signal of platform maturity in fast-moving, high-volume imaging environments

CEO Commentary

“AMRADNET is building a scalable and rapidly growing teleradiology platform, and this agreement reflects a shared commitment to expanding access to high-quality diagnostic care across the US healthcare market. The speed from evaluation to expected first productive use highlights both the operational focus of the AMRADNET team and the strength of the eUnity platform in supporting fast-moving, high-volume imaging environments. We look forward to supporting AMRADNET’s continued growth as they expand their clinical reach and imaging volumes over time.”

— Teri Thomas, Managing Director and Chief Executive Officer, Mach7 Technologies

Contract snapshot and investment significance

Detail Value
Contract term 5 years
Licence type Annual subscription
Initial contract value A$1.7M
Minimum annual studies 0.675M
Projected studies (term) Exceeds 1M
FPU timeline Within 45 days of 20 May 2026

What investors should watch next

The A$1.7M figure represents the minimum contract value, calculated on the 0.675M studies per annum floor. AMRADNET’s stated expansion into cardiology, neurology, and telemedicine services means imaging volumes could grow beyond that baseline over the 5-year term, though the announcement does not quantify the upside beyond noting volumes are projected to exceed 1M studies.

The near-term milestone to watch is FPU confirmation, expected within 45 days of 20 May 2026. Delivery on that timeline would validate Mach7’s restructured sales and services model and strengthen the case that compressed deployments are repeatable rather than contract-specific.

More broadly, this win adds to Mach7’s presence in the US market, where the company serves integrated delivery networks, national health systems, and specialist imaging providers globally.

What is a Vendor Neutral Archive and why does it underpin enterprise imaging?

A Vendor Neutral Archive (VNA) is a centralised system that stores medical imaging data independently of any single hardware or software vendor. In practical terms, this means a healthcare organisation can consolidate imaging from multiple scanner brands, software platforms, and facility types into one accessible repository, without being locked into a proprietary ecosystem.

eUnity functions as the viewer layer on top of this architecture, allowing clinicians and radiologists to access and interpret images stored within the VNA regardless of where or how they were originally captured.

For a teleradiology provider like AMRADNET, which connects radiologists to a wide range of disparate facilities remotely, this interoperability is operationally necessary. A VNA combined with a compatible enterprise viewer allows AMRADNET to onboard new facilities and imaging sources without rebuilding its workflow from scratch each time, supporting the scalable growth model the company is pursuing.

Get ASX Healthcare News Before the Market Moves

Big News Blast delivers FREE breaking ASX healthcare news and in-depth analysis directly to your inbox within minutes of release. Join 20,000+ subscribers already getting real-time alerts the moment announcements hit. Click the “Free Alerts” button at StockWire X to stay ahead of market-moving healthcare developments.


Frequently Asked Questions

What is the Mach7 Technologies AMRADNET eUnity contract?

Mach7 Technologies has signed a 5-year annual subscription agreement with US teleradiology provider AMRADNET for its eUnity Enterprise Diagnostic Viewer, with an initial contract value of A$1.7M based on a minimum of 0.675M imaging studies per annum.

What is eUnity and how does it work in a teleradiology setting?

eUnity is Mach7's Enterprise Diagnostic Viewer designed for fast, high-volume imaging workflows, allowing radiologists to remotely access and interpret medical images from disparate facilities through a scalable, cloud-compatible, and interoperable platform.

Why is the 45-day deployment timeline significant for Mach7 Technologies?

Mach7's typical deployment timeline runs to approximately 12 months, so a 45-day First Productive Use target represents a near-complete compression of that schedule, which the company attributes to internal restructuring — signalling faster time to revenue and improved scalability going forward.

What is AMRADNET and what does it do?

AMRADNET (American Radiologist Network Inc.) is a US teleradiology provider founded in 2004 that operates a SaaS-based Radiology Informatics Portal connecting board-certified radiologists with healthcare facilities for remote imaging interpretation, serving hospitals, outpatient centres, urgent care facilities, and diagnostic clinics.

What milestone should investors watch following the Mach7 AMRADNET contract announcement?

The key near-term milestone is confirmation of First Productive Use within 45 days of 20 May 2026, which would validate Mach7's restructured deployment model and support the case that compressed timelines are repeatable across future contract wins.

Josua Ferreira
By Josua Ferreira
Partnership Director
Josua Ferreira holds a Bachelor of Commerce in Marketing and Advertising and brings a background in publication, business development, and ASX market storytelling. He has worked with listed companies across the resource sector and broader market, combining sharp commercial instincts with a genuine commitment to keeping investors informed.
Learn More
Companies Mentioned in Article

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher